Encysive Drug Study Comes to an End

    February 14, 2005

Encysive Pharmaceuticals today announced topline results from the Company’s multi- center, pivotal Phase III STRIDE-2 (Sitaxsentan To Relieve ImpaireD Exercise) trial.

The trial was an effort to evaluate the safety and efficacy of Thelin (sitaxsentan) in patients with pulmonary arterial hypertension (PAH).

The trial met its primary endpoint of improved six minute walk (6MW) distance in patients receiving a 100 mg dose of Thelin, with a placebo- subtracted improvement of 31.4 meters (p=0.03). A 50 mg dose of Thelin improved 6MW by 24.2 meters, and bosentan (Tracleer), currently the only approved oral agent for treating PAH, improved 6MW by 29.5 meters. As expected, placebo patients worsened in 6MW over the 18-week period of the trial. World Health Organization (WHO) functional class also improved significantly at the 100 mg dose of Thelin versus placebo (p=0.04). There were five clinical worsening events in the 100 mg patient group, seven events in the 50 mg group, 15 events in the bosentan group, and 13 for placebo.

“We are extremely pleased with the performance of Thelin in STRIDE-2,” commented Bruce D. Given, M.D., President and Chief Executive Officer of Encysive Pharmaceuticals. “We will present more details from this trial at appropriate medical meetings over the next several months and we are now focused on filing a New Drug Application (NDA) with the U.S. Food and Drug Administration in April 2005 to seek marketing authorization. This NDA submission will be closely followed by marketing applications in Europe and other territories.”

The 100 mg dose of Thelin continued to demonstrate an encouraging safety profile. Liver function abnormalities (elevation in liver enzymes to levels >3 times the upper limit of normal) occurred in 3% of patients in the 100 mg Thelin group, compared to 5% in the 50 mg Thelin group, 11% in the bosentan group and 6% in the placebo group. Premature discontinuations due to safety or efficacy occurred in four patients at the 100 mg Thelin dose, eight at the 50 mg Thelin dose, nine in the bosentan group and 11 in the placebo group. Of these patients, adverse events contributed to the discontinuation of two patients in the 100 mg Thelin group, four in the 50 mg group, six in the bosentan group and six in the placebo group.

No serious bleeding episodes were reported in the study. Three patients had bleeding episodes in the presence of elevated international normalized ratios (INRs), one each on placebo, 50 and 100 mg of Thelin. The most frequent adverse events that occurred in patients receiving Thelin, which were more common than in placebo-treated patients, were peripheral edema (100 mg), insomnia (50 mg), chest discomfort (50 mg), sinus congestion (100 mg), nausea (50 mg), upper abdominal pain (50 mg) and increased INR (100 mg).

WebProNews | Breaking eBusiness News
Your source for investigative ebusiness reporting and breaking news.